Literature DB >> 25466942

Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.

Esther H J Hamoen1, Maarten de Rooij2, J Alfred Witjes3, Jelle O Barentsz4, Maroeska M Rovers5.   

Abstract

CONTEXT: In 2012, an expert panel of the European Society of Urogenital Radiology (ESUR) published the Prostate Imaging Reporting and Data System (PI-RADS) for prostate cancer (PC) detection with multiparametric magnetic resonance imaging (mp-MRI). Since then, many centers have reported their experiences.
PURPOSE: To review the diagnostic accuracy of PI-RADS for PC detection with mp-MRI. EVIDENCE ACQUISITION: We searched Medline and Embase up to March 20, 2014. We included diagnostic accuracy studies since 2012 that used PI-RADS with mp-MRI for PC detection in men, using prostatectomy or biopsy as the reference standard. The methodological quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool by two independent reviewers. Data necessary to complete 2×2 contingency tables were obtained from the included studies, and test characteristics including sensitivity and specificity were calculated. Results were pooled and plotted in a summary receiver operating characteristics plot. EVIDENCE SYNTHESIS: Fourteen studies (1785 patients) could be analyzed. The pooled data showed sensitivity of 0.78 (95% confidence interval [CI] 0.70-0.84) and specificity of 0.79 (95% CI 0.68-0.86) for PC detection, with negative predictive values ranging from 0.58 to 0.95. Sensitivity analysis revealed pooled sensitivity of 0.82 (95% CI 0.72-0.89) and specificity of 0.82 (95% CI 0.67-0.92) in studies with correct use of PI-RADS (ie, clear description in the methodology and no adjustment of criteria). For studies with a less strict or adjusted use of PI-RADS criteria, or unclear description of the methodology, had pooled sensitivity of 0.73 (95% CI 0.62-0.82) and specificity of 0.75 (95% CI 0.61-0.84).
CONCLUSIONS: In patients for whom PC is suspected, PI-RADS appears to have good diagnostic accuracy in PC detection, but no recommendation regarding the best threshold can be provided because of heterogeneity. PATIENT
SUMMARY: Pooling of results from all previous studies that used a relatively new 5-point scoring system for prostate magnetic resonance imaging showed that this scoring system appears to be able to detect prostate cancer accurately.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  European Society of Urogenital Radiology; Magnetic resonance imaging; Meta-analysis; Prostate Imaging Reporting and Data System (PI-RADS); Prostate cancer; Scoring method

Mesh:

Year:  2014        PMID: 25466942     DOI: 10.1016/j.eururo.2014.10.033

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  115 in total

1.  Prostate cancer: The applicability of textural analysis of MRI for grading.

Authors:  Frederick Kelcz; David F Jarrard
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

2.  Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study.

Authors:  Matthew D Greer; Anna M Brown; Joanna H Shih; Ronald M Summers; Jamie Marko; Yan Mee Law; Sandeep Sankineni; Arvin K George; Maria J Merino; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  J Magn Reson Imaging       Date:  2016-07-08       Impact factor: 4.813

Review 3.  Targeted prostate biopsy and MR-guided therapy for prostate cancer.

Authors:  David A Woodrum; Akira Kawashima; Krzysztof R Gorny; Lance A Mynderse
Journal:  Abdom Radiol (NY)       Date:  2016-05

4.  PIRADS 2.0: what is new?

Authors:  Baris Turkbey; Peter L Choyke
Journal:  Diagn Interv Radiol       Date:  2015 Sep-Oct       Impact factor: 2.630

Review 5.  Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Authors:  Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2019-07-17       Impact factor: 14.432

6.  Role of MRI for the detection of prostate cancer.

Authors:  Richard C Wu; Amir H Lebastchi; Boris A Hadaschik; Mark Emberton; Caroline Moore; Pilar Laguna; Jurgen J Fütterer; Arvin K George
Journal:  World J Urol       Date:  2021-01-04       Impact factor: 4.226

7.  Novel application of three-dimensional shear wave elastography in the detection of clinically significant prostate cancer.

Authors:  Sunao Shoji; Akio Hashimoto; Tomoya Nakamura; Shinichiro Hiraiwa; Haruhiro Sato; Yoshinobu Sato; Takuma Tajiri; Akira Miyajima
Journal:  Biomed Rep       Date:  2018-02-07

Review 8.  Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review.

Authors:  Elmira Hassanzadeh; Daniel I Glazer; Ruth M Dunne; Fiona M Fennessy; Mukesh G Harisinghani; Clare M Tempany
Journal:  Abdom Radiol (NY)       Date:  2017-01

9.  Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Authors:  Anwar R Padhani; Jeffrey Weinreb; Andrew B Rosenkrantz; Geert Villeirs; Baris Turkbey; Jelle Barentsz
Journal:  Eur Urol       Date:  2018-06-13       Impact factor: 20.096

Review 10.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.